Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: The Diabetes Prevention Program

Diabetologia

Volumn 57, Issue 3, 2014, Pages 485-490

  Franks, Paul W ^a,b,c,d   Christophi, Costas A ^d   Jablonski, Kathleen A ^d   Billings, Liana K ^e,f   Delahanty, Linda M ^e,f   Horton, Edward S ^e,f   Knowler, William C ^g   Florez, Jose C ^e,f,h  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cholesterol; Dyslipidaemia; Gene environment interaction; Gene lifestyle interaction; Genetics; Lifestyle intervention; Metformin; Pharmacogenetics; PPARGC1A; PPARGC1B; Randomised controlled trial; Triacylglycerol

Indexed keywords

CARRIER PROTEIN; GLUCOSE BLOOD LEVEL; METFORMIN; PPARGC1A PROTEIN, HUMAN; PPARGC1B PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; BODY COMPOSITION; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; FEMALE; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OBESITY; QUANTITATIVE TRAIT LOCUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; RISK REDUCTION BEHAVIOR; TRANSCRIPTION FACTORS; UNITED STATES; WEIGHT LOSS;

EID: 84894551600     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3133-4     Document Type: Article

References (30)

1. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27:728-735
2. Hoeks J, Hesselink MK, Russell AP et al (2006) Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids. Diabetologia 49:2419-2426
3. Lelliott CJ, Vidal-Puig A (2009) PGC-1beta: a co-activator that sets the tone for both basal and stress-stimulated mitochondrial activity. Adv Exp Med Biol 646:133-139
4. Patten IS, Arany Z (2012) PGC-1 coactivators in the cardiovascular system. Trends Endocrinol Metab 23:90-97
5. Barroso I, Luan J, Sandhu M et al (2006) Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 49:501-505
6. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M (2004) Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176-2184
7. Brito EC, Vimaleswaran KS, Brage S et al (2009) PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene x environment interactions in children from the European Youth Heart Study. Diabetologia 52:609-613
8. Jablonski KA, McAteer JB, de Bakker PI et al (2010) Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59:2672-2681
9. Fanelli M, Filippi E, Sentinelli F et al (2005) The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers 21:175-180
10. Hara K, Tobe K, Okade T et al (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia 45:740-743
11. Povel CM, Feskens EJ, Imholz S, Blaak EE, Boer JM, Dollé ME (2010) Glucose levels and genetic variants across transcriptional pathways: interaction effects with BMI. Int J Obes (Lond) 34:840-845
12. Franks PW, Ekelund U, Brage S et al (2007) PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia 50:569-573
13. Edwards TL, Velez Edwards DR, Villegas R et al (2012) HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes. Am J Epidemiol 175:11-21
14. 2max. Med Sci Sports Exerc 35:1998-2004
15. Lucia A, Gómez-Gallego F, Barroso I et al (2005) PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. J Appl Physiol 99:344-348
16. Sarzynski MA, Rankinen T, Sternfeld B et al (2010) Association of single-nucleotide polymorphisms from 17 candidate genes with baseline symptom-limited exercise test duration and decrease in duration over 20 years: the Coronary Artery Risk Development in Young Adults (CARDIA) fitness study. Circ Cardiovasc Genet 3:531-538
17. Stefan N, Thamer C, Staiger H et al (2007) Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92:1827-1833
18. Olesen J, Kiilerich K, Pilegaard H (2010) PGC-1alpha-mediated adaptations in skeletal muscle. Pflugers Arch 460:153-162
19. Wang L, Liu J, Saha P et al (2005) The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab 2:227-238
20. Timmers S, Konings E, Bilet L et al (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612-622
21. The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
22. The Diabetes Prevention Program Research Group (2002) The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 23:157-171
23. Fujimoto WY, Jablonski KA, Bray GA et al (2007) Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 56:1680-1685
24. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37:1217-1223
25. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X (2013) Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet 92:841-853
26. Nitz I, Ewert A, Klapper M, Döring F (2007) Analysis of PGC-1alpha variants Gly482Ser and Thr612Met concerning their PPARgamma2-coactivation function. Biochem Biophys Res Commun 353:481-486
27. Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814
28. Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248-249
29. Choi YS, Hong JM, Lim S, Ko KS, Pak YK (2006) Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun 344:708-712
30. Franks PW, Loos RJ (2006) PGC-1alpha gene and physical activity in type 2 diabetes mellitus. Exerc Sport Sci Rev 34:171-175